###### Strengths and limitations of this study

-   The clinical trial question prompt list contained 51 questions grouped under 10 headings.

-   The Quality of Informed Consent questionnaire (QuIC) is widely used to measure clinical trial participants\' actual and perceived understanding of cancer clinical trials.

-   The trial was stopped prematurely due to low accrual rates and on the advice of an independent data monitoring committee.

-   Participants had only a few minutes to review the clinical trial question prompt list (QPL) before continuing discussion about the randomised cancer treatment trial.

-   Information about the duration of the informed consent discussion in the trial is not available.

-   The time patients receiving QPL list had to review the QPL before continuing the discussion about the cancer treatment is not available.

Introduction {#s1}
============

Surveys of the public have found widespread support for the concept of clinical trials as an important and ethical means of developing improved medical care. However, only a small percentage of eligible patients are recruited to clinical trials in many institutions that promote clinical trial participation.

A significant proportion of non-trial participation is explained by patient refusal.[@R1] Reasons for trial refusal by eligible patients include concerns regarding experimentation and uncertainty and loss of control over treatment decisions. Even when patients agree to participate, they frequently do not understand basic components of the trial that they have consented to enter.[@R2] [@R3] In the UK Jenkins *et al*[@R4] audiotaped discussions between oncologists and patients during which consent was being obtained for a randomised clinical trial. In most, the concept of the trial was introduced by describing uncertainty about treatment decisions. The word randomisation was mentioned in 51 consultations (62.2%). The median duration of 'consent' interviews was \<15 min and most patients signed the consent document at the first consultation at which the clinical trial was discussed.

Brehaut *et al*[@R5] [@R6] argue that the existing approach to obtaining informed consent for clinical research may be improved by using decision aids. Juraskova *et al*[@R7] reported successful piloting of a decision aid to assist women considering participation in a breast cancer prevention trial. Spiegle *et al*[@R8] performed a systematic review to identify alternative types of decision support interventions (DSIs) for cancer treatment and a meta-analysis to compare the effectiveness of DSIs compared with patient decision aids. The study showed that the effectiveness of other DSIs, including question prompt list (QPLs) and audio recordings of the consultation, is similar to patient decision aids. This finding is important because less complex DSIs such as a targeted QPL may be all that is necessary to achieve similar outcomes as patient decision aids for cancer treatment. QPLs have been shown to increase question asking in patients with cancer.[@R9] [@R10]

The Quality of Informed Consent questionnaire (QuIC) was designed to measure participants\' actual (objective) and perceived (subjective) understanding of cancer clinical trials. Joffe *et al*[@R11] derived 13 independent domains of informed consent and wrote one or more questions to measure participants\' objective and subjective understanding of their clinical trials. After feedback from pilot testing and input from expert panels, the QuIC was sent to adult patients with cancer enrolled in phase 1, 2 and 3 clinical trials. Test--retest reliability was good, as was face and content validity. The QuIC took an average of 7.2 min to complete.

Joffe *et al*[@R2] reported the use of the QuIC to measure the quality of understanding among 207 cancer clinical trial participants in Boston who had signed a clinical trial consent form a median of 16 days earlier. Almost half of the consent discussions had lasted 1 hour. The consent form was signed a median of 6 days after the initial discussions about the trial and a quarter signed during the first consultation. There was considerable variation in the proportion of correct answers across individual questions in the QuIC.

Bergenmar *et al*[@R12] used the QuIC to survey 282 patients who had been informed in Swedish about a phase 2 or phase 3 trial and had signed a consent form. The patients were asked about the duration of the consent discussion. Thirty-nine patients (14%) reported the duration of the consent discussion was \<15 min, 139 patients (50%) responded between 15 and 30 min, and 50 patients (11%) between 45 and 60 min. The proportion of correct responses to the 16 items applicable to all patients, irrespective of trial phase was presented. High levels of knowledge (\>80%) were found for seven items, and five items were responded to correctly by 50--80% of the patients. In total, \<50% responded correctly to four items, namely risks related to the trial, the unproven nature of the trial and issues about insurances in connection to participating in the trial.

We used the QuIC to survey patients with cancer in Sydney and Melbourne who had been approached to participate in a clinical trial. The mean score on part A of the QuIC among 100 patients studied in Sydney was 76.8.[@R13] In 72 patients with cancer studied in Melbourne, the median objective knowledge score was 77.6/100, and perceived (subjective) understanding (QuIC part B) score was 91.5.[@R3] Some questions were answered particularly poorly. Higher knowledge score (QuIC part A) was associated with English as a first language. Calculation of the summary score questions included is presented in <http://jnci.oxfordjournals.org/content/93/2/139.full>. This also shows the questions that are not scored for particular phase trials.

We developed a targeted QPL for clinical trials in order to identify questions which might facilitate patient participation in clinical trial discussions with their oncologist and clinical trial nurse.[@R14] We conducted a series of focus groups with patients with cancer and their carers. The focus groups were audio-taped and transcribed. The transcripts were analysed using rigorous qualitative methodology. The final draft of the QPL was pilot tested to evaluate content validity, and acceptability and perceived efficacy in satisfying information needs about clinical trials needs and achieving involvement preference using a sample of 10 patients with cancer considering participation in a phase 3 clinical trial at each of the participating institutions. The clinicians, oncologists and clinical research nurses were encouraged to endorse and refer to the QPL during their discussion. Feedback from these patient/clinician cohorts informed the final version of the clinical trial QPL. The final version of the clinical trial QPL used in the randomised trial includes 51 questions grouped under 10 headings is presented in [figure 1](#BMJOPEN2016012666F1){ref-type="fig"}.

![Questions you may wish to ask your doctor about clinical trials. This question prompt list is intended to help you to make a decision about participating in a cancer clinical trial. It provides you with some questions that you might like to think about and ask your doctor now or later.](bmjopen2016012666f01){#BMJOPEN2016012666F1}

The aims of this study were to determine whether providing patients who are considering clinical trial participation with a QPL about clinical trials enhances: (1) the patient\'s quality of understanding of the cancer clinical trial; (2) patient achievement of his or her involvement/participation preference, (3) patient satisfaction with the informed consent to treatment decision-making process and (4) oncologist and research nurse satisfaction with the clinical trial discussion and decision-making process.

We hypothesised that patients with cancer receiving a clinical trial QPL which was endorsed by the oncologist and trial nurse prior to deciding whether to participate in a randomised cancer clinical trial compared with patients not receiving this intervention would have a higher mean knowledge score in the informed consent questionnaire (QuIC part A) (primary outcome); have enhanced achievement of their information and involvement/participation preference; and, be more satisfied with the informed consent and decision-making process. We also hypothesised that the intervention would not reduce clinical trial participation.

Methods {#s2}
=======

All patients invited to participate in a randomised cancer treatment clinical trial at three participating cancer centres were eligible for the study evaluating use of the clinical trial QPL unless the cancer treatment protocol excluded patients entered in a second randomised trial. Eligible patients were approached by a research nurse prior to their written consent to the cancer treatment trial being sought and invited to participate in the evaluation of the clinical trial question prompt list. After their written consent had been obtained, patients completed a questionnaire containing measures of information and involvement preferences,[@R15] [@R16] their attitudes to clinical trials[@R17] and their anxiety level[@R18] (see online [supplementary appendix 1](#SM1){ref-type="supplementary-material"}).

10.1136/bmjopen-2016-012666.supp1

A randomisation sequence was generated by an independent service. Patients were randomised by opening a numbered blank envelope containing the treatment group allocation: to receive or not receive the clinical trial QPL. Patients in the control group continued their discussion with the oncologist/research nurse about the clinical treatment trial. Patients randomised to receive the clinical trial QPL had at least a few minutes to review it before continuing discussion with their oncologist and/or clinical research nurse about the cancer trial proposed. During this latter discussion the clinicians specifically referred to the QPL and encouraged patients to review the list of questions. Thus participants were not blinded to intervention assignment; however, data entry personnel were blinded. There was no control of QPL exposure time nor was the time documented. There was no researcher control of items in the QPL raised by the patient or clinician.

After the decision about cancer treatment clinical trial participation, and within 3 weeks, patients were asked to complete the QuIC[@R2] and questionnaires measuring anxiety,[@R18] their satisfaction with the consent discussion and decision making[@R19] and achievement of their information and involvement preferences.[@R20] Clinician satisfaction with the informed consent process was measured using an adapted form of an existing seven-item scale measuring physician satisfaction with the decision-making process[@R21] [@R22] (see online [supplementary appendix 2](#SM2){ref-type="supplementary-material"}).

10.1136/bmjopen-2016-012666.supp2

The primary outcome measure was the QuIC. Part A of this scale contains questions covering 13 domains which are summed to produce a total score capped at 100. The authors of the QuIC reported a mean total score of 79.7 and SD of 7.7 on part A of the scale. An improvement of understanding of one entire domain score is considered to be a clinically significant improvement. A sample of 130 patients was sought for the study to have 80% power at the 5% two-sided level of significance to detect a clinically meaningful difference.

The trial accrued slowly and was stopped after 88 patients had been randomised on the advice of an independent data monitoring committee who determined that the probability of detecting a clinically meaningful difference with continued recruitment was very low (ie, the conditional power at this point in the study was well under 20%).

Eighty-eight patients were enrolled of whom 43 were males and 45 received the clinical trial QPL. Fifty-one were recruited from Royal Prince Alfred Hospital, 28 from Peter MacCallum Cancer Centre and nine from Royal Adelaide Hospital. [Table 1](#BMJOPEN2016012666TB1){ref-type="table"} presents demographic and disease details including the clinical treatment trial intervention, participating hospital and randomisation group. Patients\' attitudes to clinical trials,[@R15] clinical trial knowledge score,[@R21] [@R22] and status of completed questionnaires are also presented. Participants were balanced for gender, marital status and education level. Seventy patients completed all relevant questionnaires, but 13 in the control arm and five in the intervention arm did not complete the first and/or second questionnaires ([figure 2](#BMJOPEN2016012666F2){ref-type="fig"}).

###### 

Patient demographic, randomisation group, attitude to clinical trials

                                                        Intervention   Control
  ----------------------------------------------------- -------------- ----------
  Age                                                                  
   N                                                    45             43
   Mean                                                 57             56.9
   Median                                               58             60
   SD                                                   13.2           14.5
   Minimum                                              28             22
   Maximum                                              85             84
  Gender                                                               
   Female                                               25 (56%)       20 (47%)
  Marital status                                                       
   Never married                                        5 (11%)        7 (16%)
   Married/de facto                                     30 (67%)       30 (70%)
   Widowed                                              2 (4%)         3 (7%)
   Divorced/separated                                   7 (16%)        3 (7%)
   Other                                                1 (2%)         0 (0%)
  Education                                                            
   Year 10 or below                                     18 (41%)       16 (37%)
   Year 12                                              6 (14%)        12 (28%)
   Certificate/diploma                                  10 (23%)       8 (19%)
   University degree                                    5 (11%)        7 (16%)
   Higher degree/postgraduate                           5 (11%)        0 (0%)
  Country of birth                                                     
   Australia                                            38 (84%)       40 (93%)
   Other                                                3 (7%)         0 (0%)
   Croatia                                              1 (2%)         0 (0%)
   Italy                                                0 (0%)         1 (2%)
   Hungary                                              1 (2%)         0 (0%)
   UK                                                   1 (2%)         1 (2%)
   New Zealand                                          0 (0%)         1 (2%)
   Poland                                               1 (2%)         0 (0%)
  Hospital                                                             
   RPAH                                                 26 (58%)       25 (58%)
   PETER MAC                                            15 (33%)       13 (30%)
   Royal Adelaide                                       4 (9%)         5 (12%)
  Trial Context                                                        
   Chemotherapy for advanced disease                    22             24
   Adjuvant surgery                                     12             15
   Adjuvant radiation                                   8              7
  Specialist who was involved in the trial discussion                  
   Medical oncologist                                   20 (44%)       23 (53%)
   Surgeon                                              16 (36%)       15 (35%)
   Radiation oncologist                                 6 (13%)        4 (9%)
   Medical + radiation oncologist                       3 (7%)         1 (2%)
  Positive attitude                                                    
   N                                                    45             43
   Mean                                                 14             13.4
   SD                                                   3              4.4
   Median                                               15             15
   Minimum                                              8              0
   Maximum                                              18             18
  Negative Attitude                                                    
   N                                                    45             43
   Mean                                                 4.9            4.3
   SD                                                   2.1            2.6
   Median                                               5              4
   Minimum                                              0              0
   Maximum                                              10             10
  Clinical trial knowledge score                                       
   N                                                    45             43
   Mean                                                 4              3.6
   SD                                                   1.8            2.1
   Median                                               4              4
   Minimum                                              0              0
   Maximum                                              7              7
  Withdrawal/missing                                                   
   No                                                   40 (89%)       30 (70%)
   Did not complete questionnaire                       0 (0%)         3 (7%)
   Second questionnaire not completed                   5 (11%)        10 (23%)

Peter Mac, Peter MacCallum Cancer Centre; RPAH, Royal Prince Alfred Hospital.

![Participant flow diagram.](bmjopen2016012666f02){#BMJOPEN2016012666F2}

[Table 2](#BMJOPEN2016012666TB2){ref-type="table"} presents the results of the QuIC scores, and the Spielberger State Anxiety Inventory.[@R18] Twenty-eight of 43 patients in the control arm compared with 39 of 45 receiving the clinical trial QPL completed the informed consent questionnaire (p=0.02). There were no significant differences in the QuIC scores between the randomised groups (QuIC part A p=0.08 and QuIC part B p=0.92). We tested whether patient age or gender modified the effect of the QPL on the QuIC, and found no statistical evidence for this.

###### 

Results of the QuIC scores, and the Spielberger State Anxiety Inventory[@R18]

  Measure                                           Intervention   Control   Difference (95% CI)         p Value\*
  ------------------------------------------------- -------------- --------- --------------------------- -----------
  QuIC part A summary                                                                                    
   N                                                39             28                                    
   Mean                                             75.5           79.9      4.5 (95% CI −0.5 to 9.5)    0.080
   SD                                               9.9            10.4                                  
   Minimum                                          53.8           51.9                                  
   Maximum                                          94.2           100                                   
  QuIC part B summary                                                                                    
   N                                                39             28                                    
   Mean                                             88.4           88.1      −0.3 (95% CI −6.1 to 5.5)   0.920
   SD                                               12.1           11.4                                  
   Minimum                                          51.8           64.3                                  
   Maximum                                          100            100                                   
  Spielberger State Anxiety Inventory (follow-up)                                                        
   N                                                38             26                                    
   Mean                                             34.815         37.153    2.3 (95% CI −3.7 to 8.3)    0.438
   SD                                               10.8           13.1                                  
   Minimum                                          20             20                                    
   Maximum                                          63             66                                    

\*t-test.

QuIC, Quality of Informed Consent questionnaire.

There was no difference in anxiety between the randomised groups.

[Table 3](#BMJOPEN2016012666TB3){ref-type="table"} presents the results of patient satisfaction with the decision scores. There is no difference between the randomised groups in these results.

###### 

Patient satisfaction with decision scores

  Measure                                       Intervention   Control    p Value\*
  --------------------------------------------- -------------- ---------- -----------
  Adequately informed                                                     
   Disagree strongly                            0 (0%)         1 (4%)     
   I disagree                                   1 (3%)         0 (0%)     
   Neutral                                      2 (5%)         2 (7%)     
   Agree                                        20 (51%)       12 (43%)   
   Agree strongly                               16 (41%)       13 (46%)   
   Total                                        39             28         0.6315
  Best decision                                                           
   Disagree strongly                            0 (0%)         1 (4%)     
   I disagree                                   1 (3%)         0 (0%)     
   Neutral                                      3 (8%)         3 (11%)    
   I agree                                      13 (33%)       10 (36%)   
   Agree strongly                               22 (56%)       14 (50%)   
   Total                                        39             28         0.6575
  Consistent with values                                                  
   Disagree strongly                            0 (0%)         1 (4%)     
   Neutral                                      5 (13%)        3 (11%)    
   I agree                                      17 (35%)       12 (43%)   
   Agree strongly                               16 (42%)       12 (43%)   
   Total                                        38             28         0.6935
  Carry out decision                                                      
   Disagree strongly                            0 (0%)         1 (4%)     
   Neutral                                      2 (5%)         0 (0%)     
   I agree                                      17 (46%)       14 (50%)   
   Agree strongly                               18 (49%)       13 (46%)   
   Total                                        37             28         0.4063
  I am satisfied this was my decision to make                             
   Disagree strongly                            0 (0%)         1 (4%)     
   Neutral                                      2 (5%)         1 (4%)     
   I agree                                      13 (33%)       14 (50%)   
   Agree strongly                               24 (62%)       12 (43%)   
   Total                                        39             28         0.3002
  I am satisfied with my decision                                         
   Disagree strongly                            0 (0%)         1 (4%)     
   Neutral                                      4 (11%)        3 (11%)    
   I agree                                      14 (37%)       11 (39%)   
   Agree strongly                               20 (53%)       13 (46%)   
   Total                                        38             28         0.6806

\*Fisher\'s exact test.

[Table 4](#BMJOPEN2016012666TB4){ref-type="table"} presents the results of physician satisfaction with the consultation and with decision scores. There is no difference between the randomised groups in these results.

###### 

Clinical satisfaction with the consent consultation and with decision scores

                                                                                        Intervention   Control    p Value\*
  ------------------------------------------------------------------------------------- -------------- ---------- -----------
  I am satisfied that I provided enough information about the treatment options                                   
   Strongly disagree                                                                    1 (2%)         2 (6%)     
   Not sure                                                                             1 (2%)         1 (3%)     
   Agree                                                                                21 (51%)       21 (58%)   
   Strongly agree                                                                       18 (44%)       12 (33%)   
   Total                                                                                41             36         0.77
  I am satisfied that I clearly communicated the clinical trial and treatment options                             
   Strongly disagree                                                                    1 (2%)         1 (3%)     
   Not sure                                                                             2 (5%)         3 (8%)     
   Agree                                                                                20 (49%)       21 (58%)   
   Strongly agree                                                                       18 (44%)       11 (31%)   
   Total                                                                                41             36         0.68
  I am satisfied that I involved the patient in the decision-making process                                       
   Strongly disagree                                                                    1 (2%)         1 (3%)     
   Not sure                                                                             2 (5%)         2 (6%)     
   Agree                                                                                21 (51%)       21 (58%)   
   Strongly agree                                                                       17 (41%)       12 (33%)   
   Total                                                                                41             36         0.93
  The patient understood the clinical trial being proposed                                                        
   Strongly disagree                                                                    1 (2%)         1 (3%)     
   Disagree                                                                             0 (0%)         1 (3%)     
   Not sure                                                                             1 (2%)         3 (8%)     
   Agree                                                                                26 (63%)       25 (69%)   
   Strongly agree                                                                       13 (32%)       6 (17%)    
   Total                                                                                41             36         0.33
  Overall, I am satisfied with the decision-making process for this patient                                       
   Strongly disagree                                                                    2 (5%)         1 (3%)     
   Disagree                                                                             1 (2%)         0 (0%)     
   Not sure                                                                             2 (5%)         5 (14%)    
   Agree                                                                                22 (54%)       23 (64%)   
   Strongly agree                                                                       14 (34%)       7 (19%)    
   Total                                                                                41             36         0.32

\*Fisher\'s exact test.

Discussion {#s3}
==========

Use of the clinical trial QPL did not significantly change patient knowledge scores measured by the QuIC. The percentage of patients in the control arm completing the QuIC was significantly reduced compared with the intervention group (p=0.02). There was a trend towards lower knowledge scores (QuIC part A) in the intervention group compared with control (p=0.08). The reason for this is unknown. Patients in the control group who actually completed the assessment achieved favourable results. We hypothesise that those in the control group who comprised 28 of 43 patients in the control arm constituted a self-selected cohort of patients who were more engaged in the clinical trial process.

We have no information about the duration of the consent interviews in our trial, but it is likely that use of the clinical trial QPL extended the consent interview by a few minutes. Patients only had the QPL for a few minutes before continuing with the clinical trial consent discussion so the 'dose' of the QPL may be low, and therefore not effective. Physician endorsement of QPL use by the patient in other contexts has been an important contributor to the efficacy of QPLs.[@R23] [@R24] As QPLs have previously demonstrated benefit, it may have been these exposure and endorsement factors that prevented efficacy of the clinical trial QPL in this instance.

The patients in our trial all consented to participate in the informed consent trial at the first consultation when trial participation was sought. This finding differs from the experience reported by Joffe *et al*[@R2] where the consent form for the treatment trial was signed a median of 6 days after the initial discussion about the trial, and only 28% consented at the first consultation. There is great variation in the interval from considering participation in a clinical trial to consenting to enrol in the trial. We do not know when patients consented to participate in the cancer treatment trial but patients were asked to complete the QuIC within 3 weeks after the decision about cancer trial participation had been made.

Stryker *et al*[@R25] studied the factors associated with informed consent, patient satisfaction, and decisional regret in 87 patients who were eligible to participate in 12 selected phase 1, 2 and 3 clinical trials. They found that patients who enrolled in clinical trials quickly, may not believe they fully understand the implications of trial participation and ultimately regret their decision to participate. However, there was no relationship between timing of consent and decisional regret.

Limitations of the study include the low accrual rate, the imbalance in completion of the QuIC in the randomised groups and the brief exposure to the clinical trial QPL. Future studies of clinical trial question prompt lists should document the duration of the consent interview, the time taken for consent to be given, and consideration of when is the optimal time for patient understanding of their clinical trial to be sought.
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